OVERVIEW OF HEAD AND NECK SQUAMOUS CELL CARCINOMAS

Head and neck squamous cell carcinomas (HNSCC) are the most common head and neck cancer type and the sixth most common cancer worldwide.

 In 2018, an estimated 890,000 new cases and 450,000 HNSCC-related deaths were reported in the United States. HNSCC manifests in several regions of the head and neck, including the oral cavity, nasopharynx, oropharynx, hypopharynx, base of the tongue and tonsils, larynx, paranasal sinuses, nasal cavity, and salivary glands.

HNSCC is broadly classified as human papillomavirus (HPV)-positive (HPV+) or HPV-negative (HPV-), which is defined by the presence or absence of HPV in HNSCC tumor cells.

 Most HPV- HNSCC tumors are detected within the larynx and oral cavity, whereas HPV+ HNSCC tumors are found in the oropharynx. The majority of HNSCC cases are HPV- and are associated with risk factors including tobacco use and heavy alcohol consumption.

Although HPV+ and HPV- HNSCC are clinically, histologically, and molecularly distinct, the same therapeutic strategies are used for both, resulting in limited efficacy and clinical benefit.

 First-line treatments include surgery, radiation, and platinum-based chemotherapy. Notably, there are therapy-specific challenges, including long-term physical, psychological, and occupational effects that negatively affect quality of life for patients and their families.

 Up to 50% of patients treated for locally advanced HNSCC will experience recurrence.

 The prognosis remains poor for patients with recurrent and metastatic HNSCC; the estimated median overall survival (OS) for these patients is just 13 to 15 months.

The available United States FDA-approved therapies have limited efficacy, and survival rates for patients with recurrent and metastatic HNSCC have remained stagnant in recent years.

 In the second line, response rates for the 3 FDA-approved therapies for the treatment of HNSCC range from 13% to 16%, with progression-free survival (PFS) of approximately 2 months. Cetuximab, an EGFR inhibitor, was approved in 2006 as the first molecularly targeted agent indicated for the treatment of HNSCC.

 For more than a decade, cetuximab remained the only targeted agent available until the PD-1 and PDL-1 immune checkpoint inhibitors nivolumab and pembrolizumab received expanded indications for HNSCC in 2016 and 2019, respectively.

The majority of known genetic alterations in HNSCC cannot be therapeutically targeted, resulting in limitations to the current FDA-approved treatment options.

 is a driver oncogenic mutation that was identified as a potential therapeutic target.

 is mutated in 4% to 8% of patientswith HNSCC.

 In February 2021, the FDA granted breakthrough therapy designation to the investigational drug tipifarnib, a farnesyltransferase inhibitor (FTI), for the treatment of patients with recurrent or metastatic 

-mutant HNSCC with variant allele frequency of at least 20% after disease progression on platinum-based chemotherapy, based on the results of the RUN-HN phase 2 clinical trial.

Additional therapeutic options with better response and outcomes than those observed with currently available agents are needed for patients with recurrent and metastatic HNSCC. There is an opportunity to create novel research tools to aid the discovery of actionable molecular profiles from diverse types of HNSCC tumors.

 For example, investigators noted a need for multiplatform genetic analysis that would allow them to screen sufficient numbers of both HPV+ and HPV- tumors to support the identification of actionable biomarkers. Additionally, such a genetic screening tool could support the classification of HNSCC tumors based on their molecular profiles and account for any differences in tumor profiles collected from distinct sites in the body with HNSCC presentation.

This article discusses the dysregulated molecular pathways within HNSCC and potential therapeutic targets within these pathways that may support the development of novel targeted agents for patients with distinct oncogenic driver-mutated HNSCC. Successful targeting of novel pathways, such as the RAS-RAF family pathway, may provide an opportunity to expand the treatment landscape in HNSCC.

HNSCC GENOMIC ALTERATIONS, SIGNALING PATHWAYS, AND ACTIONABLE TARGETS

As the knowledge of the molecular landscape of HNSCC has expanded, so has knowledge of the frequency of specific oncogenic mutations in patients with HNSCC and the mutation burden of distinct HNSCC tumor types (

 HNSCC tumors demonstrate a high rate of genetic heterogeneity results in loss-of-function mutations in tumor suppressor genes (eg, 

To identify actionable biomarkers and develop novel therapies for HNSCC, there is an opportunity to better understand the pathogenesis of HNSCC at the molecular level and the influence of signaling within the tumor microenvironment.

 Select dysregulated and targetable pathways in HNSCC are shown in 

EGFR is overexpressed in 80% to 90% of patients with HNSCC and is associated with poor prognosis.

 EGFR signaling is complex; it involves several interconnected cellular signaling pathways and activation of effector molecules within downstream response cascades.

EGFR is an HER/ErbB receptor tyrosine kinase. Soluble ligands and dimerization with other HER family receptors can activate EGFR and stimulate an aggressive, prosurvival cellular signaling response by means of the PI3K/AKT/mTOR and JAK/STAT pathways and the MAPK cascade.

 EGFR also interacts with other receptors that may enhance its oncogenic potential (eg, AXL).

 As a mechanism of radiotherapy resistance, ionizing radiation can cause EGFR translocation to the nucleus, where it acts as a transcription factor and controls expression of specific genes that facilitate resistance.

EGFR can be targeted by blocking the ligand-binding domain with monoclonal antibodies, such as cetuximab, or by inhibiting the activity of the tyrosine kinase domain using small-molecule tyrosine kinase inhibitors (TKIs).

 Cetuximab binding to EGFR on the surface of both normal and tumor cells competitively inhibits the binding of ligands and blocks EGF from phosphorylating and activating EGFR.

 Cetuximab used as therapy for HNSCC is not companion diagnostic-dependent and does not require elevated EGFR expression or

Although HNSCC tumors show high rates of EGFR overexpression, the efficacy of cetuximab and other EGFR inhibitors has been limited, particularly in patients with advanced HNSCC.

 Treatment with cetuximab as a single-agent for advanced HNSCC has demonstrated an objective response rate of approximately 10%. Panitumumab, another EGFR inhibitor, was studied in combination with chemotherapy as potential frontline therapy for HNSCC but did not demonstrate improvements in OS.

HNSCC has also been shown to develop resistance to cetuximab; however, the mechanisms of cetuximab resistance, such as the effects of mutations that constitutively activate EGFR-mediated signaling, are still being explored.

Cancer immunotherapy involving checkpoint blockade has demonstrated success in treating a variety of cancers and demonstrated particular success against tumors with high rates of mutation.

 Because HNSCC has demonstrated high rates of mutation and appears to be an immunosuppressive disease, checkpoint inhibitor therapies may be beneficial for some patients.

PD-1, a T-cell coinhibitory receptor, serves as an immune checkpoint and is expressed on various immune cells, including activated and regulatory T cells, natural killer (NK) cells, activated B cells, and macrophages.

 PD-L1 is a known ligand of PD-1 that inhibits T-cell activation and limits the response to inflammation.

PD-L1 is expressed differently in HPV+ and HPV- HNSCC and may play a role in the pathogenesis of HPV+ HNSCC.

 Regulatory mechanisms inside and outside of the tumor cell cause overexpression of PD-L1. IFN-

, the best known potent cytokine inducer, has been shown to induce PD-L1 expression by upregulation of a downstream target of PI3K.

The prognostic value of PD-1/PD-L1 expression in HNSCC has yet to be determined, and there is conflicting data in the current literature available. Results from some studies suggest that elevated PD-L1 expression may be associated with HNSCC tumor size, clinical stage, metastases, and worse OS.

 Conversely, other studies suggest that lower PD-1/PD-L1 expression correlates with fewer recurrences and better outcomes, especially in patients with HPV+ tumors. One meta-analysis offers a third possibility, as no detectable differences were shown in survival outcomes among patients with PD-L1-positive and PD-L1-negative HNSCC tumors.

Nivolumab and pembrolizumab are both monoclonal antibodies that bind to PD-1 receptors and block their interaction with PD-L1 and PD-L2, which releases PD-1 pathway-mediated inhibition of the immune response, including the antitumor immune response.

 Theblocking of PD-1 activity might result in decreased tumor growth. The overall response rate to nivolumab and pembrolizumab has been much lower in patients with HNSCC than in those with Hodgkin lymphoma (15% vs 87%).

 An estimated 50% of patients with HNSCC treated with PD-1/PDL-1 inhibitors experience treatment-related adverse events that negatively affect treatment outcomes. Additional research is warranted to understand the pattern and mechanisms of PD-1/PD-L1 expression in HNSCC.

In HNSCC, most tumors demonstrate PIK3CA/RTK/RAS pathway activation through mutations or amplifications of 

 Moreover, the PI3K/AKT/mTOR pathway is upregulated in over 90% of both HPV+ and HPV- HNSCCs, which enables resistance to radiotherapy and to cytostatic drugs.

 Mutations and gene amplifications in this pathway are also associated with worsened prognosis and survival outcomes. 

 is the most commonly dysregulated oncogene in HNSCC. The HRAS/MAPK and PI3K pathways are interdependent in SCCs.

PI3K and RAS proteins are key players in the pathways that coordinate the growth, proliferation, and survival of head and neck cancer cells.

 HRAS requires PI3Kα to transform squamous epithelial cells, and helicase domain 

 mutants must bind RAS to cause cancer. Preclinical data showed that overexpression of mutant or wildtype 

 drives resistance to PI3K inhibition in 

It is possible that blocking a single pathway may not be adequate to achieve therapeutically significant reductions in 

signaling. Therefore, there is an opportunity for combination therapy regimens that target RAS in concert with other oncoproteins to control uncontrolled tumorigenesis in HNSCC.

 Notably, a combination strategy will be investigated in the phase 1/2 KURRENT trial to determine the safety and efficacy of tipifarnib plus the PI3K inhibitor alpelisib in patients with HNSCC whose tumors have HRAS overexpression or 

 mutation or amplification.23 The study was announced on July 6, 2021, and it is expected to begin this year.

The frequency of RAS-RAF family pathway activation observed in HNSCC has made this pathway a target of high therapeutic interest.

 Approximately one-third of all human cancers contain mutations in 

 mutations are frequently found in adenocarcinomas; 

 mutations are common in melanoma and certain leukemias, and 

is mutated primarily in squamous cell carcinomas (SCC), including HNSCC.

 has been identified as the predominant mutated RAS isoform in SCCs, including HNSCC, as shown in 

 is a proto-oncogene that becomes oncogenic due to mutations or increased expression.

 codes for its protein product that helps regulate cell growth and differentiation. 

-mutated HNSCC tumors generally have coincident loss of function mutations in 

 is mutated and overexpressed in certain HNSCC tumors. According to data collected from genomic sequencing and profiling studies in salivary gland cancers, 

 mutations were identified in up to 20% high-grade histologic subtypes, such as mucoepidermoid carcinoma, adenocarcinoma, and salivary duct carcinoma.

-driven tumors are found predominantly in HPV- HNSCC and are more common in certain demographic groups exposed to specific oral carcinogens (eg, tobacco and alcohol).

 In a Taiwan-based study that analyzed qualified DNA samples from male patients with oral squamous cell carcinoma (N = 120), 

 mutations were identified in 11.7% of patients. The incidence of 

 mutations was significantly higher among patients aged 56 years and older compared with younger patients (

 < .05) and in patients with substantial alcohol intake.

-mutated HNSCC has been associated with poor prognosis and limited response to treatment. Patients with 

-mutated HNSCC tumors have experienced poor overall treatment outcomes with the current treatment options available, including EGFR inhibitors and PD-1/PD-L1 inhibitors. 

 mutations were associated with less likelihood of achieving complete response or partial response to cetuximab treatment.17 Moreover, 

 mutations discovered to contribute to treatment resistance with erlotinib, another EGFR inhibitor.28

-mutant HNSCC tumors exhibit a low overall mutation burden, which is associated with poor response to immuno-oncologic agents like PD-1/PD-L1 inhibitors (eg, nivolumab and pembrolizumab).

RAS proteins serve as molecular switches that control intracellular signaling networks and play a critical role in cell proliferation, survival, and differentiation; cytoskeletal dynamism; and gene expression.

 genes can result in constitutively activated RAS leading to overexpression of RAS protein products, which can then signal many other effectors, including RAF and PI3K.

In normal, healthy cells, RAS receives and obeys signals to switch between the active GTP and inactive GDP states.24 RAS guanine nucleotide exchange factors (GEFs) convert RAS from an inactive guanosine diphosphate (GDP)-bound state to an active guanosine triphosphate (GTP)-bound state. Activation of receptor tyrosine kinases can bring RAS GEFs to the plasma membrane and begin this conversion.

 Once GTP-bound, RAS then connects with effector proteins, including the RAF kinases of the MAPK pathway and the p110 subunit of PI3K, which signal the cell to proliferate and to perform other functions. Binding with RAS GTPase-activating proteins (GAPs) then accelerates RAS GTPase activity, which terminates this signaling and returns RAS to an inactive GDP-bound state.

 mutations cause RAS proteins to maintain an active GTP state and ignore signals to switch to the inactive GDP state.

 This causes the perpetual activation of effector proteins throughout the RAS pathway to continue cell proliferation and growth. These oncogenic cells do not undergo apoptosis, and, thus, tumors are formed.

RAS proteins (HRAS, NRAS, KRAS) undergo a series of post-translational modifications. Proper overall RAS protein functions, including trafficking and localization of RAS within cells, are dependent on post-translational modifications. Hence, these modifications and the enzymes that catalyze them have become a target of therapeutic investigation.

 Farnesyltransferase and other enzymes catalyze a series of post-translational modifications, which include farnesylation, proteolysis, carboxymethylation, and palmitoylation, equipping RAS proteins with lipid groups, and initiating RAS protein trafficking to and from the plasma membrane.

Mutant RAS proteins must be localized to the plasma membrane to activate downstream signaling. This localization and activation is dependent upon attachment of a hydrophobic isoprenyl group to the C-terminal tail of RAS proteins. This is the first post-translational modification step, called prenylation.

 The predominant form of RAS prenylation is farnesylation, which is catalyzed by the enzyme farnesyltransferase. Farnesyltransferase adds a hydrophobic farnesyl group to the CAAX motif of the C-terminal tail of RAS proteins, which increases their affinity for membranes and localization of the RAS protein to the inner cell membrane (

 RAS protein binding to the inner cell membrane allows for subsequent downstream signaling and function in cell pathways.

 is inactive—without activity to carry out signaling for uncontrolled cell proliferation.

All RAS isoforms are farnesyltransferase substrates that require farnesylation for cellular membrane insertion and the subsequent activity of certain signaling proteins associated with cancer.

 On this basis, farnesyltransferase inhibitors (FTIs) could inhibit the post-translational modifications necessary for translocating RAS to the plasma membrane to prevent newly translated RAS proteins from being activated. By inhibiting downstream signaling, FTIs could result in tumor regressions in RAS-dependent malignancies.

FTI therapy research began in the 1990s, and it was originally conceived with the intent of targeting oncogenic activity in cells with 

 The clinical activity of FTI therapies studied in 

-driven tumors was underwhelming but led to the discovery of mechanisms associated with this limited response. NRAS and KRAS are susceptible to alternative prenylation events, which allow them to maintain membrane localization and pathway activation despite farnesyltransferase inhibition. Both KRAS and NRAS proteins are substrates of geranylgeranyl transferase (GGTase). When geranylgeranylated, KRAS and NRAS undergo an alternative post-translational modification in the prenylation pathway, which circumvents the mechanism and effect of FTIs. Importantly, HRAS cannot be geranylgeranylated; hence, its membrane localization and cellular function could be suppressed by an FTI. When farnesyltransferase is inhibited, KRAS and NRAS can use the alternative pathway to achieve prenylation but HRAS cannot.

Although all RAS isoforms (KRAS, NRAS, and HRAS) are farnesyltransferase substrates, 

 oncogene activity is exclusively dependent on post-translational farnesylation for membrane localization that is required for activation of downstream signaling.

 It is believed that farnesyltransferase inhibitors targeted to HRAS can prevent growth of 

-mutated tumors are predicted to be uniquely susceptible to tipifarnib-mediated inhibition of farnesyltransferase.

In HNSCC patient–derived xenograft models, FTIs induced dramatic regressions in mutant 

 and not wild-type models. Tipifarnib prevents farnesyltransferase from prenylating the HRAS protein at the CAAX motif, which, in turn, prevents HRAS membrane binding and renders the protein inactive.

 Preclinical studies of tipifarnib yielded promising results in 

-mutated HNSCC tumors, which provided the foundation for further investigation in the RUN-HN clinical trial and subsequent clinical trials for tipifarnib (presented in the next article).

There is an unmet need to address treatment challenges in the population of patients with recurrent or refractory HNSCC, as they have poor survival outcomes and limited treatment options. Current therapeutic options, including cetuximab and the 2 FDA-approved immune therapies, are associated with low rates of response in this population.

Advancements in the genomic profiling of HNSCC have greatly expanded understanding of the molecular profiles and distinct pathways that can be targeted for new therapeutic developments. 

-mutant HNSCC was identified as a targetable oncogenic mutation in 4% to 8% of the HNSCC population; these patients may benefit from disruption of 

 Tipifarnib targets oncogenic activity specifically in 

Overall, the FDA’s breakthrough-designated therapy status of tipifarnib in 2021 highlights recent progress in the development of RAS pathway-targeted therapeutic approaches; however, further investigation into the mechanisms behind post-translational modifications that regulate RAS function (eg, trafficking, signaling, activation) is needed.

Johnson DE, Burtness B, Leemans CR, CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. 

. 2020;6(1):92. doi:10.1038/s41572-020-00224-3

Beck TN, Golemis EA. Genomic insights into head and neck cancers. 

. 2016;1:1. doi: 10.1186/s41199-016-0003-z

Alsahafi E, Begg K, Amelio I, et al. Clinical update on head and neck cancer: molecular biology and ongoing challenges. 

. 2019;10(8):540. doi:10.1038/s41419-019-1769-9

Fasano M, Della Corte CM, Viscardi G, et al. Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. 

. 2021;13:1758835920949418. doi:10.1177/1758835920949418

FDA approves cetuximab to treat head and neck cancer. News release. Cancer Network®. March 31, 2006. Accessed July 22, 2021.
https://www.cancernetwork.com/view/fda-approves-cetuximab-treat-head-and-neck-cancer

Gilardi M, Wang Z, Proietto M, et al. Tipifarnib as a precision therapy for 

-mutant head and neck squamous cell carcinomas.


. 2020;19(9):1784-1796. doi:10.1158/1535-7163.MCT-19-0958

Erbitux. Prescribing information. Eli Lilly and Co; 2021. Accessed July 22, 2021. https://uspl.lilly.com/erbitux/erbitux.html#pi

Nivolumab for SCCHN. News release. US Food & Drug Administration. November 10, 2016. Accessed July 22, 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/nivolumab-scchn

Opdivo. Prescribing information. Bristol Myers Squibb Company; 2021. Accessed July 22, 2021. https://packageinserts.bms.com/
pi/pi_opdivo.pdf

FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma. News release. US Food & Drug Administration. June 10, 2019. Accessed July 22, 2021.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-first-line-treatment-head-and-neck-squamous-cell-carcinoma

Keytruda. Prescribing information. Merck & Co, Inc; 2021. Accessed July 22, 2021. https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf

Pearson AT, Vokes EE. Is this the dawn of precision oncology in head and neck cancer? 

. 2021;39(17):1839-1841. doi:10.1200/JCO.21.00569

Malone E, Siu LL. Precision medicine in head and neck cancer: myth or reality? 

. 2018;12:1179554918779581. doi:10.1177/1179554918779581

The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. 

. 2015;517(7536):576-582. doi:10.1038/nature14129.

Kura Oncology receives FDA breakthrough therapy designation for tipifarnib in head and neck squamous cell carcinoma. News release. Kura Oncology. February 24, 2021. Accessed June 3, 2021. https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-receives-fda-breakthrough-therapy-designation

Gurung AB, Bhattacharjee A. Significance of Ras signaling in cancer and strategies for its control. 

 2015;11(2):147–152. doi:10.17925/OHR.2015.11.02.147

Rampias T, Giagini A, Siolos S, et al. RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma. 

. 2014;20(11):2933-2946. doi:10.1158/1078-0432.CCR-13-2721

Gupta S, Ramjaun AR, Haiko P, et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. 

. 2007;129(5):957-968. doi:10.1016/
j.cell.2007.03.051

Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. 

. 2008;105(7):2652-2657. doi:10.1073/pnas.0712169105

Qiao XW, Jiang J, Pang X, et al. The evolving landscape of PD-1/PD-L1 pathway in head and neck cancer. 

. 2020;11:1721. doi:10.3389/fimmu.2020.01721

Chow LQM, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort

. 2016;34(32):3838-3845. doi:10.1200/JCO.2016.68.1478

Marquard FE, Jücker M. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. 

. 2020;172:113729. doi:10.1016/j.bcp.2019.113729

Kura Oncology announces clinical collaboration to evaluate tipifarnib in combination with alpelisib in head and neck squamous cell carcinoma. News release. Kura Oncology. July 6, 2021. Accessed July 22, 2021. https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-announces-clinical-collaboration-evaluate

Takashima A, Faller DV. Targeting the RAS oncogene. 

. 2013;17(5):507-531. doi:10.1517/14728222.2013.764990

Li S, Balmain A, Counter CM. A model for RAS mutation patterns in cancers: finding the sweet spot. 

. 2018;18(12):767-777. doi:10.1038/s41568-018-0076-6

Hanna GJ, Guenette JP, Chau NG, et al. Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. 

. 2020;126(17):3972-3981. doi:10.1002/cncr.33036

Su SC, Lin CW, Liu YF, et al. Exome sequencing of oral squamous cell carcinoma reveals molecular subgroups and novel therapeutic opportunities.

. 2017;7(5):1088-1099. doi:10.7150/thno.18551

Hah JH, Zhao M, Pickering CR, et al. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. 

. 2014;36(11):1547-1554. doi:10.1002/hed.23499

Ahearn IM, Haigis K, Bar-Sagi D, Philips MR. Regulating the regulator: post-translational modification of RAS. 

Articles

Updates in the Evolving Molecular Landscape of Head and Neck Squamous Cell Carcinomas

CURRENT TREATMENT LANDSCAPE OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

Head and neck squamous cell carcinoma of the head and neck (HNSCC) most frequently develops in the mucosal epithelium of the oral cavity, pharynx, and larynx.

 Histological progression of the disease begins with epithelial cell hyperplasia, followed by dysplasia (mild, moderate, and severe), carcinoma 

Some patients may present with leukoplakia or erythroplakia, which are premalignant lesions that may eventually progress to invasive cancer. However, the majority of patients present with advanced stage HNSCC without a clinical history of a premalignancy, and approximately 12% of HNSCC cases are diagnosed at the metastatic stage.

 An estimated 10% to 20% of patients treated for early-stage HNSCC experience recurrence, as well.

Patients with stage I or stage II HNSCC are typically treated with single-modality surgery or radiotherapy, which yield 5-year survival rates of approximately 90% and 70%, respectively.

 Patients with advanced and/or recurrent or metastatic (R/M) HNSCC typically require multiple treatment modalities, but, historically, few therapeutic options have been available for these patients.

Although immunotherapies have entered the treatment landscape within the past 5 years, prognosis for patients with advanced and/or R/M HNSCC remains poor.

 Only 30% of patients with advanced HNSCC are cured.

 Furthermore, HNSCC diseases are diverse and complex, and they manifest high levels of intertumoral and intratumoral heterogeneity; consequently, therapeutic responses vary widely among tumor subtypes, regardless of their clinical stages.

As discussed in the previous article, “Exploring the evolving molecular landscape of head and neck squamous cell carcinomas,” advances in genomic profiling have enabled the discovery of oncogenic mutations, such as mutated 

, for which novel targeted therapeutics can be developed.

 Furthermore, next generation sequencing (NGS) techniques can be used to screen for the presence of these mutations in patient tumors to help inform clinicians’ treatment choices and identify patients who are most likely to benefit from targeted therapies.

This article will provide an overview of the efficacy and safety of FDA–approved targeted therapies for HNSCC, as well as therapeutic gaps that still remain; discuss the clinical development of the farnesyltransferase (FTase) inhibitor (FTI) drug class with a focus on key results from tipifarnib clinical trials; and provide insights into other novel agents for which clinical trials are underway.

FDA-APPROVED TARGETED THERAPIES FOR HNSCC

The FDA has fully approved 3 targeted therapies for HNSCC: cetuximab, an EGFR inhibitor, and nivolumab and pembrolizumab, which are PD-1 checkpoint inhibitors.

 Although cetuximab targets EGFR, and nivolumab and pembrolizumab target PD-1, their use as therapies for R/M HNSCC is not driven by biomarker information.

 summarizes key efficacy and safety data for cetuximab, nivolumab, and pembrolizumab, as well as for the investigational agent tipifarnib.

In 2006, cetuximab became the first (and, for a decade, the only) targeted therapy approved to treat patients with HNSCC.

 Cetuximab is indicated in combination with radiation therapy for the initial treatment of locally or regionally advanced HNSCC, in combination with platinum-based therapy with fluorouracil (FU) for the first-line treatment of patients with recurrent locoregional disease or metastatic HNSCC, or as a single agent for the treatment of patients with R/M HNSCC for whom prior platinum-based therapy has failed.

 These indications were based on the results of the following pivotal trials, respectively: BONNER (NCT00004227), a randomized, multicenter controlled trial that enrolled adult patients with locally or regionally advanced stage III or IV HNSCC; EXTREME (NCT00122460), an open-label, randomized, multicenter controlled trial that enrolled adult patients with recurrent locoregional disease or metastatic HNSCC; and EMR 62202-016, a single-arm, multicenter clinical trial of cetuximab monotherapy in adult patients with R/M HNSCC.

The primary end point of the BONNER trial was duration of locoregional disease control; secondary end points included overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and safety for patients treated with cetuximab plus radiation (n = 211) versus radiation alone (n = 213).

 The median duration of locoregional control was 24.4 months in patients treated with cetuximab plus radiation compared with 14.9 months in patients treated with radiation alone (HR for locoregional progression or death, 0.68; 95% CI, 0.52-0.89; 

= .005). After a median follow-up of 54 months, the median OS was 49 months in patients treated with cetuximab plus radiation compared with 29.3 months in patients treated with radiation alone (

= .03). The most common grade 3 or 4 adverse events (AEs) that occurred in 10% or more of patients treated with cetuximab and radiation were mucositis (56%), dysphagia (26%), and radiation dermatitis (23%).

The primary end point of the EXTREME trial was OS for patients treated with cetuximab plus platinum-based therapy and FU (n = 222) versus the group given platinum-based therapy and FU (n = 220).

 The median OS was 10.1 months in patients given cetuximab plus platinum-based therapy and FU (95% CI, 8.6-11.2 months) versus 7.4 months in those given platinum-based therapy and FU (HR for death, 0.80; 95% CI, 0.64-0.99; 

The PFS and best response rates were among the secondary end points of the EXTREME trial. In patients treated with cetuximab plus platinum-based therapy plus FU, PFS was 5.6 months versus 3.3 months for patients treated with platinum-based therapy and FU alone (HR, 0.54; 95% CI, 0.43-0.67; 

 Overall best response to therapy was 36% (odds ratio, 2.33; 95% CI, 1.5%-3.6%; 

Most patients (82%, n = 179) treated with cetuximab plus platinum-based therapy and FU experienced a grade 3 or 4 AE.

 The most common grade 3 or 4 AEs occurring in 10% or more of patients in the group given cetuximab plus platinum-based therapy and FU included neutropenia in 49 patients (22%), anemia in 239 patients (13%), and thrombocytopenia in 24 patients (11%).

EMR 62202-016 aimed to determine the scope of cetuximab activity in patients with R/M HNSCC who already progressed on platinum-based therapy by comparing the intent-to-treat efficacy data from previous phase 2 studies with a retrospective study of a similar group of patients who were treated outside of clinical trials.

 The primary end point was response to treatment, defined as the best confirmed response.

Response rates (which included complete response [CR] and partial response [PR]), median survival, and median progression were similar among patients treated cetuximab monotherapy (n = 103), cetuximab plus cisplatin or carboplatin (n = 96), or cetuximab plus cisplatin (n = 79).

 In the cetuximab group, 13% (95% CI, 7%-21%) of patients responded to treatment compared with 10% of both patients taking cetuximab plus cisplatin or carboplatin (95% CI, 5%-18%) and those taking cetuximab plus cisplatin (95% CI, 5%-18%). The median OS of patients in the cetuximab group was 5.9 months (95% CI, 4.9-7.1) compared with 6.1 months (95% CI, 4.9-7) in those using cetuximab plus cisplatin or carboplatin and 5.2 months (95% CI, 3.1-6) in patients given cetuximab plus cisplatin.

These results show that although cetuximab in combination with radiation or chemotherapy may significantly prolong OS compared with either radiation or chemotherapy alone in a front-line setting, OS rates are still low, and treatment response durations are short.

 The efficacy of cetuximab monotherapy is also much lower than its efficacy in combination with chemotherapy or the efficacy of chemotherapy alone.

 Furthermore, most patients who are treated with cetuximab plus platinum-based therapy plus FU will experience severe AEs that could negatively impact their quality of life (QOL).

Updates in the Evolving Molecular Landscape of Head and Neck Squamous Cell Carcinomas | Supplements and Featured Publications

Updates in the Evolving Molecular Landscape of Head and Neck Squamous Cell Carcinomas

Advancements in the Development of Targeted Agents for Head and Neck Squamous Cell Carcinomas